TORONTO, ONTARIO--(MARKET WIRE)--Oct 30, 2008 -- OccuLogix, Inc. (NasdaqCM:OCCXD - News)(Toronto:OC.TO - News) announced today that it has been notified by the NASDAQ Listing and Hearing Review Council (the "Listing Council") that OccuLogix has demonstrated compliance with the U.S.$1 minimum bid price rule and the requirement to maintain stockholders' equity in the minimum amount of U.S.$2,500,000. The Listing Council confirmed that the listing review is now closed and that the Company's securities will remain listed on The NASDAQ Capital Market.

About OccuLogix, Inc.

OccuLogix (www.occulogix.com) is a healthcare company focused on ophthalmic devices for the diagnosis and treatment of age-related eye diseases. Its wholly-owned subsidiary, OcuSense, Inc. (www.ocusense.com), is an in-vitro diagnostics company developing and commercializing novel, laboratory-on-a chip technologies that enable eye care practitioners to test for highly sensitive and specific biomarkers in tears at the point-of-care.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about the Company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.

     Contacts:
     OccuLogix, Inc.
     Eric Donsky
     Chief Executive Officer
     (858) 794-1400
     Email: edonsky@tearlab.com
     Website: http://www.occulogix.com